USC’s Keck School of Medicine partners with StemCardia to advance heart failure treatment

FHS
October 8, 2024
11:28 pm

The Keck School of Medicine of USC has launched a strategic collaboration with StemCardia, a biotechnology company, founded by a Keck School of Medicine faculty member, that develops cellular and genetic therapies to address heart failure.

Candid Health Secures $29M for Revenue Cycle Automation Platform

What You Should Know: – Candid Health, the innovative revenue cycle automation platform designed for healthcare providers raises $29M in a Series B funding round

September 14, 2024

Promising gene therapy could transform heart failure treatment

A new gene therapy can reverse the effects of heart failure and restore heart function in a large animal model.

December 10, 2024

SCHOTT Pharma reinforces commitment to align its climate actions to the requirements of the Paris Agreement – Biotech Investments

EQS-News: SCHOTT Pharma AG & Co. KGaA / Key word(s): ESG SCHOTT Pharma reinforces commitment to align its climate actions to the requirements of the

August 9, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.